Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDEN trial of early switch maintenance versus delayed second-line nivolumab in advanced squamous NSCLC
2016-003030-24Phase 3Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in Pulmonary squamous cell carcinoma (2 arms), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Overall survival. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2016-003030-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003030-24.